WASHINGTON, D.C. – AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker on Secretary of Commerce Gina Raimondo’s trip to China:
“With the ongoing policy complexities facing the medtech industry in China and around the world, AdvaMed® is encouraged by Secretary Raimondo’s trip to China to further engagement on the critical economic and commercial issues between our two countries. AdvaMed® is committed to working with our domestic and global partners to ensure patients, regardless of where they live, have access to life-saving medical technology, so these high-level government meetings are essential to address our concerns about the uncertainties our members face in the Chinese market.”
# # #
Related Reading
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 6/27
June 30, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 6/20
June 20, 2025
Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update
June 16, 2025
Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.
Blog / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Tariffs
Medtech is Essential: Industry Supports Call for Tariff Flexibility
May 29, 2025
AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
URGENT: Court Ruling on Tariffs — Implications for Medtech
Now On Demand!
Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!
News / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Tariffs
Swiss Medtech and AdvaMed Call for Zero for Zero Tariffs and Recognition of FDA Approvals and Clearances
May 20, 2025
Bern/Washington – Swiss Medtech, the leading trade association for medical technology companies in Switzerland, and AdvaMed, the U.S. Medtech Association and the world’s largest organization representing medtech innovators, are jointly calling for reciprocal “zero for zero” tariffs between the two countries.
News / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Tariffs
AdvaMed Testifies in U.S. Senate
May 14, 2025
WASHINGTON – Today, President and CEO Scott Whitaker of AdvaMed, the Medtech Association, testified before the U.S. Senate Committee on Finance in its hearing focused on the impact of tariffs on U.S. supply chains. AdvaMed was the only health care organization invited to discuss the medical technology supply chain.
News / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed, U.K. Medtech Association Call for Flexibility on Tariffs, “Regulatory Convergence”
May 6, 2025
WASHINGTON—AdvaMed, the Medtech Association, the world’s largest organization representing medtech innovators, and the Association of British HealthTech Industries (ABHI), the leading trade association for medical technology companies in the United Kingdom, are calling for reciprocal “zero for zero” tariffs between the two countries and greater regulatory convergence, noting the prominence of medtech in both the U.S. and U.K. health care systems and economies and the critical need to avoid disruptions in patient care that tariffs could cause in both countries.